LFMD LIFEMD INC

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

The preferred dividend will be paid on April 15, 2024 to holders of record at the close of business on April 5, 2024.

About LifeMD

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit .

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact

Marc Benathen, Chief Financial Officer

Media Contact

Jessica Friedeman, Chief Marketing Officer



EN
26/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE

LifeMD Reports First Quarter 2024 Results; Raises Full Year Revenue Gu...

LifeMD Reports First Quarter 2024 Results; Raises Full Year Revenue Guidance First quarter revenue increased 33% year-over-year to $44.1 million with telehealth revenue growing 53% versus the year-ago period.Raising full-year revenue guidance to at least $205 million, up from prior guidance of at least $200 million.Growth in all business segments, with weight management subscribers growing to 42,000 as of March 31, 2024. As of today, weight management subscribers exceed 50,000.Including the increase in deferred revenue from prepaid weight management subscriptions, cash-adjusted EBITDA was $...

 PRESS RELEASE

LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-...

LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve outcomes NEW YORK and BOSTON, May 02, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: LFMD), a leading provider of virtual primary care services, and , a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing...

 PRESS RELEASE

LifeMD Appoints Dr. Calum MacRae to its Board of Directors

LifeMD Appoints Dr. Calum MacRae to its Board of Directors NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. “We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to impr...

 PRESS RELEASE

LifeMD to Report First Quarter 2024 Financial Results on May 8

LifeMD to Report First Quarter 2024 Financial Results on May 8 NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on May 8, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Wednesday, May 8thTime:4:30 p.m. Eastern timeToll-Free Dial-In:1-888-886-7786International Dial-In:1-416-764-8658Conference ID:51137398Live & Archived Web...

 PRESS RELEASE

LifeMD to Participate in Upcoming Investor and Industry Conferences Du...

LifeMD to Participate in Upcoming Investor and Industry Conferences During May NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor and industry conferences during the month of May: BTIG Obesity Health Forum, May 8, 2024. Management will participate in a virtual panel titled Obesity Management with Coaching, Eating, and Lifestyle Management moderated by equity research analyst David Larsen.Citizens JMP Securities Life Sciences Conference, May 13-14...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch